IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 8, May 2026
Impact Factor: 8.2

Oral Drug Delivery: Overcoming Challenges of First-Pass Metabolism and Improving Absorption

Mr. Pritesh Anil Gaykar and Ms. Kalyani Bhor
Samarth Institute of Pharmacy, Belhe, Ahmadnagar

Abstract: *Oral administration remains the preferred route for drug delivery due to its convenience and patient compliance. However, its effectiveness is often hampered by the first-pass effect, where drugs undergo significant metabolism in the liver before reaching systemic circulation, reducing bioavailability. This necessitates higher doses and potentially compromises efficacy. This review explores strategies to overcome these challenges and improve oral drug absorption. Novel drug delivery systems, including nanoparticles, lipid-based formulations, and prodrugs, are highlighted for their ability to protect drugs from degradation, enhance intestinal permeability, and facilitate targeted delivery, ultimately leading to improved therapeutic outcomes. Additionally, understanding and modulating factors like drug solubility, ionization, and efflux mechanisms are crucial for optimizing oral bioavailability. By addressing these challenges, researchers aim to unlock the full potential of oral drug delivery, ensuring effective and targeted therapy for patients.*

Keywords: *Oral administration*

I. INTRODUCTION

To enhance oral drug delivery and overcome first-pass metabolism, formulations can include prodrugs, nanoparticles, or permeation enhancers. Additionally, designing drugs with better lipophilicity and stability can improve absorption, while technologies like microneedles or mucoadhesive systems can enhance mucosal delivery. Sustained-release formulations, such prolonged-release tablets or capsules, can support the maintenance of therapeutic levels over an extended period of time in long-term oral drug administration. Drugs can be shielded from deterioration by lipid-based formulations and nanoparticles, while absorption issues can be resolved by adding bioavailability enhancers. To ensure sustained efficacy, drug delivery methods must be tailored to individual pharmacokinetic profiles

Advantages of Long-Term Oral Drug Delivery:

- Patient Compliance: Oral administration is convenient, contributing to higher patient adherence in long-term treatments.
- Stable Plasma Levels:Sustained-release formulations lead to stable and prolonged drug concentrations, optimizing therapeutic outcomes.
- Cost-Effective: Oral drug delivery often incurs lower costs compared to alternative routes, promoting affordability and accessibility.

Challenges:

- First-Pass Metabolism: The liver's metabolic processes may significantly reduce the bioavailability of certain drugs, necessitating strategies to bypass or mitigate this effect.
- Variable Absorption: Variability in gastrointestinal absorption can impact drug efficacy, requiring precise formulation to ensure consistent therapeutic levels.
- Gastrointestinal Conditions: Factors like pH, enzymes, and transit times in the gastrointestinal tract can affect drug absorption, posing challenges in maintaining consistent drug release.

DOI: 10.48175/IJARSCT-35555

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 8, May 2026
Impact Factor: 8.2

- Formulation Complexity: Developing sustained-release formulations can be complex, requiring specialized technologies and expertise, potentially increasing development costs.

Addressing these challenges involves a multidisciplinary approach, integrating pharmaceutical sciences, pharmacokinetics, and formulation technologies to optimize long-term oral drug delivery.

First pass metabolism:-

First-pass mechanisms refer to the initial metabolism or alteration of a drug as it passes through the liver before entering systemic circulation. This can significantly impact a drug's bioavailability, efficacy, and potential side effects.

The liver's enzymatic activity during first-pass metabolism can either activate, deactivate, or modify drugs. One example is the conversion of prodrugs into their active forms. For instance, codeine undergoes first-pass metabolism to morphine, its active metabolite, which provides pain relief.

Understanding first-pass mechanisms is crucial in drug development as it influences dosage, administration routes, and overall therapeutic

Factors affecting absorption:-

Several factors can influence the absorption of drugs in the body:

- Drug Properties: The chemical properties of a drug, such as solubility, size, and ionization, affect its ability to cross cell membranes.
- Route of Administration: Different administration routes (oral, intravenous, subcutaneous, etc.) impact the rate and extent of drug absorption.
- Blood Flow to the Site of Absorption: Adequate blood supply to the absorption site enhances drug absorption.
- Surface Area for Absorption: Larger surface areas, like the small intestine, allow for more absorption compared to smaller areas.
- pH Environment: The pH of the gastrointestinal tract can influence the ionization of drugs, affecting their absorption.
- Concentration of the Drug: Higher drug concentrations often lead to increased absorption until a saturation point is reached.
- Presence of Food: Some drugs are better absorbed in the presence of food, while others are absorbed more efficiently on an empty stomach.
- Interactions with Other Substances: Interactions with other drugs or substances can impact absorption positively or negatively.
- Metabolism in the Gut Wall: Some drugs undergo metabolism in the gut wall before reaching systemic circulation.

Considering these factors is crucial in optimizing drug delivery and ensuring therapeutic efficacy.

Enzyme inhibitors Mechanism of action Challenges and limitations:-

Mechanism of Action:Enzyme inhibitors interfere with the activity of enzymes, affecting various physiological processes. There are different types of enzyme inhibitors:

Competitive Inhibitors: These compete with the substrate for binding to the enzyme's active site. They can be overcome by increasing the substrate concentration.

Non-competitive Inhibitors: Bind to a site on the enzyme other than the active site, altering the enzyme's shape and function.

Uncompetitive Inhibitors: Bind to the enzyme-substrate complex, preventing the release of the product.

Challenges and Limitations:

Specificity Issues: Achieving specificity for the target enzyme without affecting other essential enzymes can be challenging.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 8, May 2026 Impact Factor: 8.2

Off-Target Effects: Inhibitors may unintentionally affect other biological pathways, leading to side effects.
Resistance Development: Prolonged use may lead to the development of resistance, reducing the inhibitor's effectiveness.
Toxicity: Some inhibitors may have toxic effects, limiting their therapeutic window.
Delivery Challenges: Getting the inhibitor to the target site in adequate concentrations can be challenging, especially for certain tissues or intracellular targets.
Reversibility: The reversibility of inhibition varies, and designing inhibitors with the desired kinetics can be complex.
Patient Variability: Individual variations in enzyme levels and activity among patients can impact the inhibitor's efficacy.
Understanding these challenges is crucial in the development and application of enzyme inhibitors for therapeutic purposes



BENEFITS	VS	RISKS
Non-invasive route		**Product development**
Local vs. systemic		Lack new smart materials & novel formulations
Treat range of diseases		Hostile gut environment
Beyond liver		Dose/loading
Non-viral delivery		**Translation**
Deliver various nucleic acids		Manufacturing & scale-up
Plug & play technology		Supply chain & quality
Reproducible manufacturing		Regulatory hurdles

Table 1 Advanced formulations for oral delivery of poorly water-soluble drugs summary.

Delivery system modification Nanoparticulate carriers, Advantages and limitations, Lipid-based formulations, Mechanism of action, Examples:-

Nanoparticulate Carriers:

Advantages:

1. Improved Drug Solubility: Nanoparticles can enhance the solubility of poorly soluble drugs.
2. Targeted Drug Delivery: Enables targeted delivery to specific tissues or cells, minimizing side effects.
3. Controlled Release: Allows for sustained and controlled release of the drug over time.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 8, May 2026 Impact Factor: 8.2

4. Protection of Drug: Nanocarriers can protect drugs from degradation, enhancing stability.
5. Increased Bioavailability: Enhances drug absorption and bioavailability.
6. Versatility: Can be tailored for various administration routes.

Limitations:

1. Complex Manufacturing: Fabricating nanoparticles can be intricate and may require specialized equipment.
2. Biocompatibility: Concerns regarding the biocompatibility and potential toxicity of some nanoparticulate materials.
3. Regulatory Challenges: Regulatory approval for nanoparticulate drug delivery systems can be demanding.

Lipid-Based Formulations:

Mechanism of Action:

1. Improved Solubility: Lipids can solubilize hydrophobic drugs, aiding in their absorption.
2. Formation of Lipid Bilayers: Lipid-based formulations can form lipid bilayers, facilitating drug transport across cell membranes.
3. Enhanced Bioavailability: Lipid-based formulations can improve the bioavailability of poorly water-soluble drugs.
4. Lipid Digestion: In the case of oral administration, lipids undergo digestion in the gastrointestinal tract, aiding drug absorption.

Examples:

1. Liposomes: Spherical lipid vesicles used for drug delivery.
2. Nanoemulsions: Small droplets of oil dispersed in water, improving drug solubility.
3. Solid Lipid Nanoparticles (SLNs): Nanoscale lipid particles with a solid core.

Understanding these delivery systems provides insights into optimizing drug formulations for enhanced therapeutic outcomes.



Enhancing solubility Salt formation Complexation with cyclodextrins:-

Enhancing solubility can be achieved through various methods, including salt formation and complexation with cyclodextrins. Salt formation involves converting a drug into its salt form, often using salts that are more soluble in water. This improves the drug's dissolution and bioavailability. Cyclodextrins, on the other hand, form inclusion complexes with drugs, enhancing their solubility by encapsulating them within their hydrophobic cavities. Both approaches are valuable strategies in pharmaceutical formulation to improve the solubility and ultimately the effectiveness of drugs.

Increasing permeability Chemical modification of the drug Penetration enhancers:-

To enhance drug permeability, chemical modifications of the drug molecule can be employed. This may involve altering the structure to improve solubility, stability, or bioavailability. Additionally, penetration enhancers can be utilized to increase drug absorption through the skin or mucous membranes by temporarily disrupting the barrier

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 8, May 2026
Impact Factor: 8.2

properties. Common enhancers include surfactants, fatty acids, and complexing agents. However, careful consideration is essential to balance effectiveness and safety in drug delivery systems.

II. CONCLUSION

In conclusion, addressing the challenges of first-pass metabolism and enhancing absorption is crucial for optimizing oral drug delivery. Strategies such as prodrug design, nanoparticle formulations, and permeation enhancers play pivotal roles in overcoming these hurdles. By modifying drug structures to bypass metabolic degradation and employing innovative delivery systems that enhance absorption, researchers aim to improve bioavailability and therapeutic efficacy. This multifaceted approach contributes significantly to the advancement of oral drug delivery, fostering the development of more effective and patient-friendly pharmaceuticals, ultimately promoting better treatment outcomes and patient compliance. The continual exploration of these strategies holds promise for advancing the field and addressing the complexities associated with oral drug administration.

REFERENCES

[1]. Banerjee, K. Ibsen, T. Brown, R. Chen, C. Agatemor, S. Mitragotri, Ionic liquids for oral insulin delivery, Proc. Natl. Acad. Sci. U. S. A., 115 (2018), pp. 7296-7301

[2]. D.J. Brayden, M.J. Alonso Oral delivery of peptides: opportunities and issues for translation Adv. Drug. Deliv. Rev., 106 (2016), pp. 193-195

[3]. M. Vertzoni, P. Augustijns, M. Grimm, M. Koziolek, G. Lemmens, N. Parrott, C. Pentafragka, C. Reppas, J. Rubbens, J. Van Den Alphabeele, T. Vanuytsel, W. Weitschies, C.G. Wilson

[4]. Impact of regional differences along the gastrointestinal tract of healthy adults on oral drug absorption: an UNGAP review

[5]. B.J. Boyd, C.A.S. Bergstrom, Z. Vinarov, M. Kuentz, J. Brouwers, P. Augustijns, M. Brandl, A. Bernkop-Schnurch, N. Shrestha, V. Preat, A. Mullertz, A. Bauer-Brandl, V. Jannin

[6]. Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems

[7]. P.S. Kowalski, A. Rudra, L. Miao, D.G. Anderson Delivering the messenger: advances in technologies for therapeutic mRNA delivery

[8]. Dressman J. B., Reppas C. (2016). Oral drug absorption: prediction and assessment. Boca Raton: CRC Press. [Google Scholar]

[9]. Amidon G. L., Lennernas H., Shah V. P., Crison J. R. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (3), 413–420. 10.1023/a:1016212804288 [PubMed] [CrossRef] [Google Scholar]

[10]. Aungst B. J. (2012). Absorption enhancers: applications and advances. Aaps J. 14 (1), 10–18. 10.1208/s12248-011-9307-4 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

[11]. Avdeef A. (2001). Physicochemical profiling (solubility, permeability and charge state). *Curr. Top. Med. Chem*. 1 (4), 277–351. 10.2174/1568026013395100 [PubMed] [CrossRef] [Google Scholar]

[12]. Bachar M., Mandelbaum A., Portnaya I., Perlstein H., Even-Chen S., Barenholz Y., Danino D. (2012). Development and characterization of a novel drug nanocarrier for oral delivery, based on self-assembled β-casein micelles. *J. Control Release*. 160 (2), 164–171. 10.1016/j.jconrel.2012.01.004 [PubMed] [CrossRef] [Google Scholar]

[13]. Brewster M. E., Loftsson T. (2007). Cyclodextrins as pharmaceutical solubilizers. *Adv. Drug Deliv. Rev*. 59 (7), 645–666. 10.1016/j.addr.2007.05.012 [PubMed] [CrossRef] [Google Scholar]

[14]. Charman W. N., Porter C. J. H. (1996). Lipophilic prodrugs designed for intestinal lymphatic transport. *Adv. Drug Del. Rev*. 19 (2), 149–169. 10.1016/0169-409x(95)00105-g [CrossRef] [Google Scholar]

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 8, May 2026
Impact Factor: 8.2

[15]. Chen J., Blevins W. E., Park H., Park K. (2000). Gastric retention properties of superporous hydrogel composites. *J. Control Release*. 64 (1), 39–51. 10.1016/s0168-3659(99)00139-x [PubMed] [CrossRef] [Google Scholar]

[16]. Guo L. Q., Fukuda K., Ohta T., Yamazoe Y. (2000). Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. *Drug Metab. Dispos*. 28 (7), 766–771. [PubMed] [Google Scholar]

[17]. Choi J. S., Jo B. W. (2004). Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. *Int. J. Pharm*. 280 (1–2), 221–227. 10.1016/j.ijpharm.2004.05.014 [PubMed] [CrossRef] [Google Scholar]

[18]. Choudhury H., Gorain B., Madheswaran T., Pandey M., Kesharwani P., Tekade B. W. (2018). *Drug complexation implications in drug solubilization and oral bioavailability enhancement. Dosage form design considerations*. Amsterdam: Elsevier, 473–512. [Google Scholar]

[19]. Custodio J. M., Wu C. Y., Benet L. Z. (2008). Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. *Adv. Drug Deliv. Rev*. 60 (6), 717–733. 10.1016/j.addr.2007.08.043 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

[20]. Dahan A., Hoffman A. (2008). Rationalizing the selection of oral lipid based drug delivery systems by an *in vitro* dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. *J. Control Release*. 129 (1), 1–10. 10.1016/j.jconrel.2008.03.021 [PubMed] [CrossRef] [Google Scholar]

[21]. Dahlgren D., Lennernäs H. (2019). Intestinal permeability and drug absorption: predictive experimental, computational and *in vivo* approaches. *Pharmaceutics*. 11 (8), 411. 10.3390/pharmaceutics11080411 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

[22]. Dahmani F. Z., Yang F., Zhou J., Yao J., Zhang T., Zhang Q. (2012). Enhanced oral bioavailability of paclitaxel in pluronic/LHR mixed polymeric micelles: preparation, *in vitro* and *in vivo* evaluation. *Eur. J. Pharm. Sci*. 47 (1), 179–189. 10.1016/j.ejps.2012.05.015 [PubMed] [CrossRef] [Google Scholar]

[23]. De Villiers M. M., Melgardt M., Pornanong A., Glen S. (2008). *Nanotechnology in drug delivery*. Berlin: Springer Science and Business Media. [Google Scholar]

[24]. de Waard H., Cathcart H. W., Hinrichs W. L. J. (2011). Bottom-up preparation techniques for nanocrystals of lipophilic drugs. *Pharm. Res*. 28 (5), 1220–1223. 10.1007/s11095-010-0323-3 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

[25]. Desai M. P., Labhasetwar V., Amidon G. L., Levy R. J. (1996). Gastrointestinal uptake of biodegradable microparticles: effect of particle size. *Pharm. Res*. 13 (12), 1838–1845. 10.1023/a:1016085108889 [PubMed] [CrossRef] [Google Scholar]

[26]. DiMarco R. L., Hunt D. R., Dewi R. L., Heilshorn S. C. (2017). Improvement of paracellular transport in the Caco-2 drug screening model using protein-engineered substrates. *Biomaterials*. 129, 152–162. 10.1016/j.biomaterials.2017.03.023 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

[27]. Dintaman J. M., Silverman J. A. (1999). Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). *Pharm. Res*. 16 (10), 1550–1556. 10.1023/a:1015000503629 [PubMed] [CrossRef] [Google Scholar]

[28]. Dong J., Sun Q., Wang J. Y. (2004). Basic study of corn protein, zein, as a biomaterial in tissue engineering, surface morphology and biocompatibility. *Biomaterials*. 25 (19), 4691–4697. 10.1016/j.biomaterials.2003.10.084 [PubMed] [CrossRef] [Google Scholar]

[29]. Dressr G. K., Spence J. D., Bailey D. G. (2000). Pharmacokinetic–pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. *Clin. Pharmacokinet*. 38 (1), 41–57. 10.2165/00003088-200038010-00003 [PubMed] [CrossRef] [Google Scholar]

[30]. Dressman J. B., Reppas C. (2016). *Oral drug absorption: prediction and assessment*. Boca Raton: CRC Press. [Google Scholar]

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 8, May 2026
Impact Factor: 8.2

[31]. Duhem N., Rolland J., Riva R., Guillet P., Schumers J. M., Jérome C., Préat V., et al. (2012). Tocol modified glycol chitosan for the oral delivery of poorly soluble drugs. *Int. J. Pharm*. 423 (2), 452–460. 10.1016/j.ijpharm.2011.12.010 [PubMed] [CrossRef] [Google Scholar]

[32]. Fatouros D. G., Karpf, D. M., Nielsen, F. S., Mullertz, A. (2007). Clinical studies with oral lipid based formulations of poorly soluble compounds. *Ther. Clin. Risk Manag*. 3 (4), 591–604. [PMC free article] [PubMed] [Google Scholar]

[33]. Food and Drug Administration (1998). *Guidance for industry: general considerations for pediatric pharmacokinetic studies for drugs and biological products*. Rockville: US Department of Health and Human Services. [Google Scholar]

[34]. Gaucher G., Dufresne M. H., Sant V. P., Kang N., Maysinger D., Leroux J. C. (2005). Block copolymer micelles: preparation, characterization and application in drug delivery. *J. Control Release*. 109 (1), 169–188. 10.1016/j.jconrel.2005.09.034 [PubMed] [CrossRef] [Google Scholar]

[35]. Goldberg D. S., Vijayalakshmi N., Swaan P. W., Ghandehari H. (2011). G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity. *J. Control Release*. 150 (3), 318–325. 10.1016/j.jconrel.2010.11.022 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

[36]. Ghandehari M., Barnett C. C., Schwarz B. E., Karnes W. E., Redfern J. S., and Feldman M. (1991). Effect of age on gastric acid secretion and serum gastrin concentrations in healthy men and women. *Gastroenterology*. 101 (4), 977–990. 10.1016/0016-5085(91)90724-y [PubMed] [CrossRef] [Google Scholar]

[37]. Greenwald R. B., Conover C. D., Choe Y. H. (2000). Poly(ethylene glycol) conjugated drugs and prodrugs: a comprehensive review. *Crit. Rev. Ther. Drug Carrier Syst*. 17 (2), 101–161. 10.1615/critrevtherdrugcarriersyst.v17.i2.20 [PubMed] [CrossRef] [Google Scholar]

[38]. Han L., Xu R., Wong A. (2014). Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy. *Biomaterials*. 35 (15), 4589–4600. 10.1016/j.biomaterials.2014.02.027 [PubMed] [CrossRef] [Google Scholar]

[39]. Hauss D. J. (2007). Oral lipid-based formulations. *Adv. Drug Deliv. Rev*. 59 (7), 667–676. 10.1016/j.addr.2007.05.006 [PubMed] [CrossRef] [Google Scholar]

[40]. Hauss D. J. (2007). Oral lipid-based formulations. *Adv. Drug Del. Rev*. 59 (7), 667–676. 10.1016/j.addr.2007.05.006 [PubMed] [CrossRef] [Google Scholar]

[41]. Hauss D. J. (2013). *Oral lipid-based formulations: enhancing the bioavailability of poorly water-soluble drugs*. Boca Raton: CRC Press. [Google Scholar]

[42]. Hayashi M., Swaan M., Awazu S. (1997). Transcellular and paracellular contribution to transport processes in the colorectal route. *Adv. Drug Del. Rev*. 28 (2), 191–204. 10.1016/s0169-409x(97)00072-0 [CrossRef] [Google Scholar]

[43]. He C., Yin L., Tang C., Yin C. (2013). Multifunctional polymeric nanoparticles for oral delivery of TNF-α siRNA to macrophages. *Biomaterials*. 34 (11), 2843–2854. 10.1016/j.biomaterials.2013.01.033 [PubMed] [CrossRef] [Google Scholar]

[44]. Hirayama F., Uekama K. (1999). Cyclodextrin-based controlled drug release system. *Adv. Drug Deliv. Rev*. 36 (1), 125–141. 10.1016/s0169-409x(98)00058-1 [PubMed] [CrossRef] [Google Scholar]